SANTA CLARA, Calif., 12 Jan. Affymetrix, Inc., (Nasdaq: AFFX) today announced that it is launching the GeneChip® Consortia Design Program, a collaborative initiative that will bring Affymetrix and plant and animal research communities together to create novel whole-genome arrays. Under the new program, Affymetrix will underwrite the design fees required to produce the new arrays, putting industry-standard GeneChip technology within reach of virtually any research community.

 

Genomic community groups have already embraced this new initiative and there are currently plans to produce 12 new array designs under the Consortia Design Program this year: wheat, rice, poplar, corn, pig, cow, chicken, grape, soy, tomato, cotton and citrus.

 

"We have selected Affymetrix as our microarray platform of choice for the Vitis (grape) microarray consortia because Affymetrix GeneChip arrays are robust, reliable, easy to use, highly reproducible, and cost-effective," said John C. Cushman, Ph.D., Professor of Biochemistry at the University of Nevada, Reno and a member of the International Grape Genome Consortia. "Affymetrix arrays use 11 probe pairs of 25 mers per transcript giving multiple independent measurements of hybridization. Multiple probe pairs offer the best specificity without compromising sensitivity, and are more accurate than a single longer oligo measurement. Not only will the data quality be extremely high, but a single platform within the Vitis community will allow any number of data comparisons to be made within and across laboratories."

 

Affymetrix has worked closely with genomic community groups worldwide for several years, developing Drosophila, Pseuodomonas, Arabidopsis, Barley, Xenopus and Zebrafish whole-genome arrays via the catalog and CustomExpress™ programs. By waiving the array design fee and helping these groups with sequence selection and other design issues, the Consortia Design Program will offer genomic community groups an opportunity to consolidate their sequence data on the Affymetrix industry standard array platform.

 

"The rapidly growing number of sequences for a wide variety of organisms, the increasing popularity of the GeneChip array system and the success of our other collaborative designs contributed to our decision to start the consortia program," said Lianne McLean, Director, Gene Expression Marketing, Affymetrix. "Perhaps the biggest factor is the way that our arrays are being embraced by the academic community. Over 2,000 peer reviewed papers have been published using Affymetrix technology, with over 1,000 published just last year alone."

 

Past consortia designs have shown that Affymetrix collaborative design process helps ensure that the content on the array is as comprehensive as possible and meets the communities' needs. Additionally, engaging the worldwide community in the design effort has prompted researchers to include previously unpublished EST data, increasing the total amount of information available and improving the quality of the final design.

 

All content and annotations from the Consortia Design Program arrays will be hosted in the NetAffx Data Analysis Center at www.affymetrix.com. This online resource integrates access to the data generated by Affymetrix' GeneChip arrays with biological information available in a broad range of public and private databases. Regular annotation updates will be provided by Affymetrix at no cost to these communities.

 

About Affymetrix:

Affymetrix is a pioneer in creating breakthrough tools that are driving the genomic revolution. By applying the principles of semiconductor technology to the life sciences, Affymetrix develops and commercializes systems that enable scientists to improve the quality of life. The Company's customers include pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products companies as well as academic, government and other non-profit research institutes. Affymetrix offers an expanding portfolio of integrated products and services, including its integrated GeneChip® platform, to address growing markets focused on understanding the relationship between genes and human health. Additional information on Affymetrix can be found at www.affymetrix.com.

 

All statements in this press release that are not historical are "forward- looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses, uncertainties relating to technological approaches, manufacturing, product development, market acceptance (including uncertainties relating to product development and market acceptance of the GeneChip(R) Consortia Design Program), personnel retention, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2002 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

 

NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix, Inc.